Fragile X syndrome is a genetic disorder caused by a single gene mutation in the Fragile X Mental Retardation 1 gene.
The FMR1 gene exists in three different forms: normal, premutation and full mutation.
For those with a full mutation, the results can include a wide range of developmental, physical and behavioural problems and is the most common cause of inherited developmental disability and the most common single-gene cause of autism.
The condition usually comes with a normal life expectancy, but also requires lifelong care and support.
The Azrieli Foundation supports FMR1 research of both premutation and full mutation.
![](https://azrielifoundation.flightdeckmedia-staging.com/wp-content/uploads/2019/05/yellow-horizontal-spacer.png)
“Metformin is the Aspirin of the 21st century.”
Dr. Randi Hagerman
Metformin Clinical Trial on Individuals with Fragile X Syndrome
Some of the symptoms are language deficits, behavior problems, obesity and excessive appetite.
Metformin is a Type 2 diabetes medication that, as Dr. Randi Hagerman from the MIND Institute in California explains, is the “Aspirin of the 21st century”.
The Metformin Clinical Trial is a collaboration between the UC Davis MIND Institute, the University of Alberta Women and Children’s Health Research Institute in Edmonton, and the University of Montreal CHU Sainte-Justine Research Centre.
The network of researchers, along with an infrastructure for collaborative clinical trials, will help the universities jointly conduct this trial of a new and potentially promising targeted treatment.
Metformin clinical trial progress meeting, Banff 2019.
![Photo of researchers of Metformin clinical trial for Fragile X treatment at Banff, Alberta.](https://azrielifoundation.flightdeckmedia-staging.com/wp-content/uploads/2019/09/Metformin-Clinical-Trial-Progress-Meeting-Banff-2019.jpg)
![](https://azrielifoundation.flightdeckmedia-staging.com/wp-content/uploads/2019/05/yellow-horizontal-spacer.png)
Fragile X Premutation Clinic at Sheba Medical Center
For individuals who have a repeated gene sequence that results in a premutation, the results are less obvious but can be equally devastating.
A carrier of a genetic mutation is a person who inherits an altered form of a gene but may show no effects of that mutation.
However, in Fragile X, this definition does not exactly fit, as carriers of a premutation are at risk to develop Fragile X-associated disorders including Fragile X Tremor Ataxia Syndrome and Fragile X Associated Primary Ovarian Insufficiency.
For women who carry the premutation, their children have up to a 50% chance of carrying the mutation.
Worldwide, approximately 1 in 200 women and 1 in 450 men are carriers of the premutation form of the gene.
Sheba Medical Center is both researching and advancing care of those with the Fragile X premutation.
![](https://azrielifoundation.flightdeckmedia-staging.com/wp-content/uploads/2019/05/yellow-horizontal-spacer.png)
Prof. Irit Sagi: MMP9 Study
At the Weizmann Institute in Israel, Prof. Irit Sagi is exploring whether there is a connection between the high levels of MMP9 in the brain and the behavioural and cognitive traits of those with Fragile X.
![](https://azrielifoundation.flightdeckmedia-staging.com/wp-content/uploads/2019/05/Neurodevelopment-Icon.png)